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Massive Mitochondrial Degeneration in Motor Neurons Triggers the
Onset of Amyotrophic Lateral Sclerosis in Mice Expressing a
Mutant SOD1
Jiming Kong1 and Zuoshang Xu2
Departments of 1Pharmacology and Molecular Toxicology and 2Cell Biology, University of Massachusetts Medical School,
Worcester Foundation Campus, Shrewsbury, Massachusetts 01545
Amyotrophic lateral sclerosis (ALS) involves motor neuron de-
generation, skeletal muscle atrophy, paralysis, and death. Mu-
tations in Cu,Zn superoxide dismutase (SOD1) are one cause of
the disease. Mice transgenic for mutated SOD1 develop symp-
toms and pathology similar to those in human ALS. To under-
stand the disease mechanism, we developed a simple behav-
ioral assay for disease progression in mice. Using this assay, we
defined four stages of the disease in mice expressing G93A
mutant SOD1. By studying mice with defined disease stages,
we tied several pathological features into a coherent sequence
of events leading to motor neuron death. We show that onset of
the disease involves a sharp decline of muscle strength and a
transient explosive increase in vacuoles derived from degener-
ating mitochondria, but little motor neuron death. Most motor
neurons do not die until the terminal stage, ;9 weeks after
disease onset. These results indicate that mutant SOD1 toxicity
is mediated by damage to mitochondria in motor neurons, and
this damage triggers the functional decline of motor neurons
and the clinical onset of ALS. The absence of massive motor
neuron death at the early stages of the disease indicates that
the majority of motor neurons could be rescued after clinical
diagnosis.
Key words: ALS; mitochondria; SOD1; paralysis; motor neu-
ron; degeneration; spinal cord
Amyotrophic lateral sclerosis (ALS) involves motor neuron loss
leading to progressive skeletal muscle atrophy and death (Mulder
et al., 1986; Munsat, 1989). Despite a long history of clinical and
pathological studies, the pathological progression for ALS has
not been clearly defined. This is largely attributable to difficulties
in correlating clinical symptoms and motor neuron loss in human
patients. At least two possible models could explain the progres-
sive nature of clinical symptoms. The first is that at the onset of
muscle weakness the patient has already gone through an ex-
tended period of gradual motor neuron death. The emergence of
symptoms reflects an exhausted functional compensation by the
remaining motor neurons. Therefore, a large fraction of motor
neurons have already been lost, and the clinical course reflects the
loss of the remaining motor neurons. The second possibility is
that at the onset of muscle weakness (or clinical disease) there is
little or no motor neuron death, but there is a decline of motor
neuron function. As the degenerative process proceeds, motor
neurons gradually die, eventually leading to paralysis and death
of the patient. The distinction between these two models has
important implications for prognosis and therapy. New animal
models developed recently for ALS have made it possible to
distinguish between these two models.
ALS occurs in sporadic (SALS) and familial (FALS) forms
(Mulder et al., 1986; Munsat, 1989). Mutations in the SOD1 gene
are one genetic cause for FALS (Rosen et al., 1993; Brown, 1995).
Several mouse models that express the mutated genes develop
motor neuron degeneration similar to that in humans (Gurney et
al., 1994; Ripps et al., 1995; Wong et al., 1995; Bruijn et al., 1997).
The initial characterization of these mouse lines has proven that
a dominant gain of an “adverse property” by the mutated en-
zymes causes motor neuron degeneration (for review, see Bruijn
and Cleveland, 1996; Tu et al., 1997). In addition, these analyses
confirmed numerous pathological features that have been ob-
served in humans (Hirano, 1991; Chou, 1992), including axonal
spheroids (Tu et al., 1996), increase of ubiquitin (Wong et al.,
1995; Bruijn et al., 1997), Lewy body-like inclusions (Wong et al.,
1995; Bruijn et al., 1997), fragmentation of Golgi apparatus
(Mourelatos et al., 1996), and selective loss of motor neurons
(Gurney et al., 1994; Ripps et al., 1995; Wong et al., 1995; Bruijn
et al., 1997). The most prominent new feature is the large number
of membrane-bound vacuoles in G93A and G37R lines (Dal
Canto and Gurney, 1995; Wong et al., 1995). These vacuoles
emerge before the end stage of the disease and appear to be
derived from dilated mitochondria (Dal Canto and Gurney, 1995;
Wong et al., 1995) and endoplasmic reticulum (Dal Canto and
Gurney, 1995).
In these early studies, pathological changes were correlated
with the age of animals but not with disease stage. Because of the
highly heterogeneous onset and duration of the disease in indi-
vidual animals (see below), the subjects of study at any age were
a mixture of individuals at different disease stages. Consequently,
pathological changes seen in animals of the same age were not
necessarily the ones that develop at the same disease stage.
Similarly, pathological features that appear in younger animals do
not necessarily precede those seen in older animals in disease
progression. Transient changes, which correspond to specific dis-
ease stages, are particularly difficult to recognize. In short, patho-
logical studies without definition of the disease stage cannot
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delineate the sequence of events leading to motor neuron death
and thus do not use the full potential of these transgenic animal
models.
To effectively study these models, we have conducted the first
experiments to analyze pathological changes in the context of
clinical progression. We first developed a simple, objective assay
to measure muscle strength in mice and used this assay to follow
the clinical progression in a transgenic line that expresses the
G93A SOD1 mutation (Gurney et al., 1994). We then quantita-
tively measured several pathological features in the mice with
defined disease stages. We show that the disease progression goes
through four stages, each with specific and time-dependent fea-
tures. Of particular interest are the early stages in which mito-
chondrial abnormalities are the most prominent feature and neu-
ronal function declines sharply, whereas neuronal death is
minimal. Thus, mitochondrial degeneration is an important early
event in triggering the decline of motor neuron function and,
consequently, clinical disease. The minor motor neuron loss for a
substantial period after the onset of clinical disease offers a
period of time after diagnosis to rescue the majority of motor
neurons.
MATERIALS AND METHODS
Human SOD1 transgenic mice. Mice transgenic for the mutated human
SOD1 G93A (TgN[SOD1-G93A]1Gur) and wild-type human SOD1
(TgN[SOD1]2Gur) were purchased from The Jackson Laboratory (Bar
Harbor, ME) and bred in the University of Massachusetts Medical
School animal facility. Both lines were originally made and characterized
by Gurney et al. (1994). The survival of the purchased lines was pro-
longed in comparison with the original line because of a reduced number
of transgene copies (http:// lena.jax.org/resources/documents/imr/
SODletter.html). The transgenic mice were identified using the PCR
method described by Gurney et al. (1994).
Muscle strength test. The test was conducted using a device designed in
this laboratory. Mice were allowed to grab onto a vertical wire (2 mm in
diameter) with a small loop at the lower end. A vertical wire allows mice
to use both fore- and hindlimbs to grab onto the wire. Although in the
first few tests some mice used forelimbs predominantly, they usually
learned to use all four limbs after a few trials. This results in a significant
improvement during the first three trials, after which the performances
stabilize. Thus, both the fore- and hindlimbs contribute to the measured
muscle strength in this assay.
The wire was maintained in a vertically oriented circular motion (the
circle radius was 10 cm) at 24 rpm. Early tests indicated that maintaining
the wire in motion gave much more consistent measurements than a
stationary wire. The time that the mouse was able to hang onto the wire
was recorded with a timer. Because most mice fell within 5 min, we cut
off testing at 300 sec to test more animals in a limited time period. Mice
were usually tested once a week starting when they were 90 d old, and
testing continued until they could no longer hang onto the wire.
Morphological analysis. Animal fixation, tissue dissection, and micro-
scopic analysis were performed as described previously (Xu et al., 1993).
In brief, mice were anesthetized and perfused with a solution of 4%
paraformaldehyde and 2.5% glutaraldehyde in 0.1 M phosphate buffer,
pH 7.6. Tissues were kept in the same solution for further fixation. The
L4 and L5 spinal nerve roots and lumbar spinal cords (a 2 mm segment
centered at the L5 root entry level) were dissected out and post-fixed with
2% osmium tetroxide in 100 mM cacodylate buffer, pH 7.6. After dehy-
dration in graded alcohol, the tissue blocks were embedded in Epon.
Sections (1 mm) were stained with toluidine blue and examined with light
microscopy.
For quantification of ventral roots, complete microscopic pictures of L4
and L5 ventral roots were taken from 1 mm transverse sections and
digitized using a Nikon LS-1000 scanner. The area and equivalent radius
of all axons in a ventral root larger than 1.5 mm in diameter were
measured using MetaMorph software (Universal Imaging Corporation,
West Chester, PA). Degenerating axons were counted directly under
light microscope.
To quantify motor neurons in spinal cord, serial transverse sections 8
mm thick were cut from Epon-embedded L5 lumbar spinal cord. Every
fifth section (five sections total from each animal) was collected and
stained with toluidine blue. All neurons with nuclei and located in the
lateral motor column (as defined in Fig. 1) were drawn using a Nikon
drawing tube. The drawings were scanned into computer using an HP
flat-bed scanner. Several parameters, including the number and size of
motor neurons and their nuclear size, were measured from these draw-
ings using MetaMorph software.
To measure vacuoles, two ventral horns were photographed from a 1
mm transverse section of the spinal cord. The picture frame contained an
area 280 3 433 mm in size and covered about three-quarters of the
ventral horn. These images were digitized using a Nikon LS-1000 scan-
ner. Measurements were performed using MetaMorph image analysis
software. Vacuoles were quantified using the threshold function. Non-
vacuolar structures such as nuclei and large blood vessels were manually
eliminated from the measurement. Capillary vessels were usually indis-
tinguishable from the vacuoles under the light microscope and therefore
were included in the measurement. However, this background was esti-
mated by making the same measurements in wild-type animals.
For electron microscopy, thin sections of ventral horn were cut from
the Epon tissue blocks, stained with uranyl acetate and lead citrate, and
visualized using a Philips EM-400 transmission electron microscope.
RESULTS
Mouse ALS undergoes four functional declining stages
To follow disease progression in G93A mice, we developed a
simple and objective assay to measure muscle strength. In this
assay, the time that a mouse was able to hang onto a wire was
measured as an indication of muscle strength (see Materials and
Methods). We first tested mice in different age groups, which
revealed an age-dependent decline of hanging time for G93A
mice, but not for wild-type mice (WT) and wild type human
SOD1 (WS) transgenic mice (Fig. 2A).
To determine how muscle weakness develops in individual
Figure 1. The definition of L5 lateral ventral horn where neuronal num-
bers were quantified was derived as follows. Perpendicular to the midline
M, line N passing the central canal was drawn. Parallel to line N and across
point B was line L. Point B was the first point on the contour of the ventral
gray matter (tracing from the midline) at which the contour made a .180°
turn. Connecting point C (the cross-point of line N and the contour of gray
matter) and point D (at one-third the distance from point B to A), line P
was drawn. All neurons within the area encompassed by line P and the
contour of ventral horn (hatched area) were drawn and measured.
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animals, we tested G93A and wild-type animals once a week
beginning at 90 d of age and continued the tests until the G93A
mice could no longer hold onto the wire. The results revealed
several interesting aspects of muscle strength change. First, both
the onset and the duration of muscle strength decline were highly
variable among different individuals, ranging from age 113 to
188 d for the former and 35 to 94 d for the latter (Fig. 2B, Table
1). Second, the time course of muscle strength change apparently
went through four different stages (Fig. 2C,D): a pre-muscle
weakness stage (PMW), during which muscle strength was main-
tained at the normal level; a rapid declining stage (RD), during
which the hanging time declined sharply (usually by .50% within
a period of 2 weeks); a slow declining stage (SD), which followed
the RD stage and lasted for 4–11 weeks; and a paralysis stage
(Para), during which paralysis of limbs began and the mouse
could no longer hold onto the wire (Fig. 2C,D). The sharp decline
in muscle strength during the RD stage suggests that there may be
a synchronized pathological change at the onset of the disease.
Pathological progression in motor axons at
different stages
To elucidate the sequence of events leading to motor neuron
death, and in particular to see whether there is a synchronized
loss of motor neurons at the onset of the disease, we examined the
motor axons in ventral roots (Fig. 3). We found few pathological
Figure 2. Four stages of muscle strength change in G93A mice. The time that mice were capable of hanging onto a wire was measured as an indication of
muscle strength. A, Age-dependent decline of muscle strength in G93A mice. Groups of mice at different ages were tested. The number of mice in each age
group ranged from 3 to 20. G93A, Mutant SOD1 mice; WT, nontransgenic (wild-type) mice; WS, wild-type SOD1 transgenic mice. Error bars indicate SEM.
B, Highly variable onset of muscle weakness among different G93A mice. Each trace represents measurements from one animal. For clarity, only measurements
around the RD stage in 20 animals are shown. C, Synchronized plot of muscle strength decline in individual G93A mice. Zero week represents the time point
just before the decline begins. For clarity, only 10 traces are shown. D, Average time course of muscle strength decline in G93A mice (n 5 12). PMW, Pre-muscle
weakness stage; RD, rapid declining stage; SD, slow declining stage; Para., paralysis stage. Error bars represent SEM.
Table 1. ALS onset and duration in the G93A mice
Range Average 6 SD n
RD onseta 113–188 151 6 17 72
Para onsetb 183–253 211 6 18 23
Durationc 35–94 65 6 19 23
a The age (days) at which a sharp decline in hanging time was first detected.
b The age (days) at which the mouse could no longer hold onto the wire.
c The period between the last day that the mouse displayed a normal hanging time
and the first day that the mouse could no longer hold onto the wire.
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changes in the PMW stage (Fig. 3C) compared with the WT (Fig.
3A) or WS (Fig. 3B) mice. Surprisingly, the sharp muscle strength
decline during the RD stage was not correlated with a loss of a
large number of motor axons (Fig. 3D). Instead, for a long period
during the SD stage (up to 50 d after the onset of RD), a
significant fraction of motor axons remained (Fig. 3E–G). It was
not until the paralysis stage that the vast majority of motor axons
became degenerated (Fig. 3H).
To quantify the changes in motor axons, we measured the axon
size and number in the L4 and L5 ventral roots. As the disease
developed, there was a progressive loss of large motor axons after
the onset of muscle weakness (Fig. 4). Two features of this loss
have emerged from this analysis. First, two processes, atrophy
and degeneration, contributed to the loss of large axons during
the early stages. This was particularly evident when the axons
were divided into two groups, one larger and the other smaller
than 4.5 mm in diameter. Beginning from the RD stage, there was
a significant loss of large motor axons (Fig. 5). Meanwhile, the
number of small axons was increased up to 20 d after the onset of
muscle weakness, before it reverted back to the original number
(Fig. 5). These results indicate that large motor axons undergo
atrophy before degeneration.
Second, taking into account the substantial fraction of atrophic
large axons, the actual fraction of degenerated large axons during
the SD phase was relatively low (Table 2). As long as paralysis
had not begun, even at 50 d after the onset of muscle weakness,
the fraction of degenerated large axons was ,50% (Figs. 3–5,
Table 2), which implies that more than half of the large motor
neurons were still alive. The largest single loss of motor axons
occurred at the paralysis stage (Fig. 5, Table 2), when the majority
of large motor neurons were lost permanently. These data indi-
cate that the vast majority of motor neurons are still alive when
muscle weakness develops, and the initial muscle weakness re-
flects motor neuron dysfunction rather than loss (see below).
Thus, there is a period of time to rescue motor neurons after
muscle weakness begins.
Pathological progression in ventral horn motor
neurons at different stages
To investigate the sequence of events in the vicinity of motor
neuron cell bodies, we analyzed changes in the ventral horn spinal
cord at different disease stages. Consistent with changes in motor
axons, there were considerable numbers of neurons remaining in
the ventral horn after muscle weakness began (Fig. 6D–G).
Quantification of neuronal number and size in the lateral ventral
horn showed a selective loss of large neurons (Fig. 7A). However,
this was not evident until 33 d after the onset of muscle weakness
(Fig. 7A). At the paralysis stage, most of large motor neurons
were lost, whereas the number of small neurons was unaffected
(Figs. 6H, 7A).
Figure 3. Axonal degeneration in L5 ventral roots at different stages of ALS in G93A mice. Plastic sections (1 mm) were stained with toluidine blue.
A, WT; B, WS; (C–H), G93A at the following stages: (C) PMW, (D) RD, (E–G) 20, 33, and 50 d after the onset of RD, respectively; H, paralysis.
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The most prominent change in the early stages of the disease
was vacuolation. At the PMW stage, there was a slight increase of
vacuoles (Figs. 6C, 7B) compared with WT (Figs. 6A, 7B) and WS
(Figs. 6B, 7B) mice. However, vacuoles were greatly increased at
the onset of the disease (RD stage) (Figs. 6D, 7B). Although
conspicuous throughout the SD stage, the number of vacuoles
gradually declined toward the end stage of the disease (Figs.
6E–H, 7B). But the size of vacuoles increased slightly from the
RD stage until 33 d after the onset of muscle weakness, and then
declined as the disease progressed toward the paralysis stage (Fig.
7C). These results indicate that the massive vacuolation in motor
neurons is transient in the disease process and suggest that small
vacuoles may fuse or cluster before being lost with the motor
neurons.
Mitochondrial damage precedes the onset of
the disease
The light microscopic data described above showed only a minor
increase in vacuoles during the PMW stage. To determine what
change(s) triggers the onset of RD stage, we used electron mi-
croscopy (EM) to examine the spinal cords. The most prominent
feature at the PMW stage was abnormal mitochondria, which
were present in abundance in dendrites and axons but scarce in
the cell bodies. Shown in Figure 8 are several examples of mito-
chondrial changes, including those with dilated and disorganized
cristae (Fig. 8A,B), leakage of the outer membrane (Fig. 8A,
arrow), broken outer membrane (Fig. 8C, arrows), and early
vacuoles that still carry remnants of mitochondria (Fig. 8D,E,
Figure 4. Axon size distribution in L4 and L5 ventral roots. The distri-
bution of axons in the two roots was similar, and therefore the measure-
ments were pooled together in one plot. Three animals were measured for
each plot. The three PMW animals ( C) were between 120 and 160 d old
and therefore were near the RD stage. A–H, Same as in Figure 2.
Figure 5. Motor axons undergo atrophy before degeneration. A, Total
number of axons in L4 and L5 ventral roots at different disease stages. B,
Number of axons larger than 4.5 mm in diameter at different disease
stages. C, Number of axons smaller than 4.5 mm in diameter at different
disease stages. D, Number of degenerating axons in L4 and L5 ventral
roots at different disease stages. Asterisks indicate significance level in
comparison with the WT using two-tailed Student’s t test. One asterisk
represents p , 0.05; two asterisks represent p , 0.01. n 5 3 for all stages.
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Figure 6. Changes in ventral horn at
different disease stages. Plastic sections
(1 mm) were stained with toluidine blue.
A–H, Same as in Figure 2.
Table 2. Axon number changes (%) in L4 and L5 ventral roots
Stage PMW RD 20 d 33 d 50 d Para
Total axons 26.2 29.8 219.3 224.1 230.6 261.9
Large axons 219.5 223.9 247.1 245.7 252.5 286.0
Large 3 small 10.9 10.3 20.2 12.1 9.9 2.8
Degenerated large axons 28.6 213.6 226.9 233.6 242.6 283.3
The percent reduction in total axon number and large axon number is calculated in reference to wild-type mice. The definition of large and small axons is described in the
text (also see Fig. 5). The fraction of large axons that become small (large3 small) is estimated by subtracting the small axon number in the wild-type mice from that of the
G93A mice at different stages. The difference between the total lost large axons and the fraction of the large axons that become small (large3 small) is the fraction of large
axons that are degenerated.
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arrows). The abnormal mitochondria often appeared swollen
compared with the normal ones in adjacent synaptic terminals
(Fig. 8C, arrowheads). Densely accumulated neurofilaments can
be seen in axons in close proximity with vacuoles (Fig. 8D) and
also at many other proximal axon sites without vacuoles (data not
shown), suggesting that slow axonal transport begins to fail before
the onset of the RD stage. At the RD stage, abundant vacuoles in
dendrites as well as in axons were seen, some of which were no
longer carrying the remnants of mitochondria (Fig. 8F). Only
rarely were vacuoles present in cell bodies.
DISCUSSION
Pathological observations without correlation with disease stages
are largely a description of scattered phenomena and provide only
limited information regarding the mechanism of disease progres-
sion. Because of difficulties involved in studying human cases,
particularly because of the near impossibility of obtaining patho-
logical specimens at the early stages of the disease, descriptions of
end-stage disease have dominated the study of ALS since the
original identification of the disease more than a century ago
(Chou, 1992; Hirano, 1991). Transgenic mice expressing mutated
SOD1 have provided an unprecedented opportunity to study the
early stages of the disease. Indeed, several new pathological
features including mitochondrial vacuolation and early astroglio-
sis were revealed (Dal Canto and Gurney, 1995; Wong et al.,
1995; Morrison et al., 1996; Bruijn et al., 1997).
In all studies preceding the current work, pathological features
were correlated with age of animals but not with stage of the
disease. As shown in Figure 1, the onset and duration of disease
in mice mirrors human disease (Cudkowicz et al., 1997; Juneja et
al., 1997) and are highly heterogeneous. As a result, it was difficult
to determine the sequence of events in the disease progression
and the significance of the pathological features that were ob-
served. To solve this problem, we used a novel approach by
developing an assay to determine the disease stages and analyzing
pathological changes in mice with defined disease stages. By this
approach, a coherent picture of the functional and pathological
progression of ALS in the G93A mice begins to emerge (Fig. 9).
The progression of ALS in G93A mice can be divided into four
stages based on changes in muscle strength, and each of these
stages is correlated with specific pathological features. The PMW
stage ( just before the RD stage) shows little difference from the
wild type under the light microscope. However, abundant mito-
chondrial abnormalities can be found by EM (Fig. 8). The onset
of muscle weakness (RD stage) correlates with a massive mito-
chondrial vacuolation, signifying the beginning of a degenerative
process in motor neurons that compromises their function (Fig.
9). The SD stage correlates with axonal atrophy and a gradual loss
of motor neurons (Fig. 9). However, the majority of motor neurons
are alive until the very end stage of the disease (Fig. 9, Table 2).
Several implications can be drawn from these results. First,
abundant mitochondrial abnormalities are the most prominent
pathological feature before the onset of muscle strength decline.
In addition, the onset of a sharp muscle strength decline is
correlated with a massive mitochondrial vacuolation. This is the
first demonstration that mitochondrial degeneration is associated
with the onset of the disease and suggests that the “gained
toxicity” of the mutant SOD1 damages mitochondria, triggering
the decline of motor neuron function and the onset of clinical
disease. Second, the vacuolation is a transient process. It corre-
lates with the onset of muscle weakness but decreases toward the
end stage of the disease. It has been pointed out that vacuoles
were not a noted feature in human ALS (Bruijn et al., 1997). Our
results raise the possibility that vacuoles are also an integral part
of human ALS, but they exist only at the very early stages of the
disease. Therefore, the lack of vacuoles in human ALS could be
attributed to the fact that the pathological examination is per-
formed on patients at the terminal stage of the disease.
Third, the initial muscle weakness signifies a stage in which the
degenerative process in large motor neurons begins to compro-
mise their function. However, it does not represent a massive loss
(or death) of these neurons. The loss of the majority of motor
neurons does not occur until the paralysis stage, the end stage of
the disease. The presence of the majority of motor axons during
the RD and SD stages indicates that even after the muscle
weakness begins, most motor neurons have not died and thus
could be rescued by effective therapeutic intervention. Fourth,
axonal atrophy has been noted in human ALS patients (Chou,
1992), but it was difficult to determine whether this decrease was
Figure 7. Changes in spinal cord at different disease stages. A, Changes
in the number of neurons in the ventral horn. All numbers were averages
from two animals and were normalized to the average number of neurons
in each wild-type mouse (145 neurons). Filled bars, Total number of
neurons; open bars, number of neurons with diameters ,25 mm; shaded
bars, number of neurons with diameters .25 mm. Note that the division
of large and small neuronal groups at 25 mm diameter is arbitrary because
there was not a clear division of large and small neuron peaks in the size
distribution (data not shown). Changes in vacuole number (B) and
vacuole size (C) at different disease stages. Two ventral horns were
measured in each animal. The small number of vacuoles in the WT mice
are capillary blood vessels that could not be distinguished from the real
vacuoles under the light microscope. Asterisks indicate significance level in
comparison with the WT, using two-tailed Student’s t test. One asterisk
represents p , 0.05; two asterisks represent p , 0.01. n 5 3 for all stages.
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caused by the death of large axons or a shift of large axons to
small ones. Our results show that large axons become atrophic
before degeneration (Fig. 4, Table 2). This suggests that there is
a failure in axonal transport at the early stage of ALS, which is
consistent with the proximal accumulation of neurofilaments ob-
served during the PMW and RD stages in this study (Fig. 8), as
well as in another study at unspecified disease stages (Tu et al.,
1996).
Previous studies have noted the presence of vacuoles. However,
the origin of the vacuoles has been controversial (Dal Canto and
Gurney, 1995; Wong et al., 1995). One study proposes that vacu-
oles are derived from dilation of endoplasmic reticulum and
mitochondria (Dal Canto and Gurney, 1995), whereas the other
study contends that vacuoles are derived from degenerating mi-
tochondria (Wong et al., 1995). By determining the precise time
of the disease onset, the current study shows that abundant
abnormal mitochondria, including those with dilated cristae and
the early vacuoles with mitochondrial remnants, are present be-
Figure 8. Mitochondrial abnormalities at PMW ( A–E) and RD ( F) stages. A, A swollen dendritic mitochondrion with dilated cristae (asterisk) and
leaking outer membrane (arrow). B, Swollen dendritic mitochondria with dilated and disorganized cristae. A synaptic terminal on the dendrite contains
normal mitochondria (arrowhead). C, A proximal dendrite containing mitochondria with broken outer membranes (arrows). Adjacent synaptic terminals
contain normal mitochondria (arrowheads). D, Early vacuoles in a proximal axon. Arrows point to mitochondrial remnants. E, Early vacuoles in a
dendrite. Arrows point to mitochondrial remnants. F, Massive dendritic vacuolation at the RD stage.
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fore the massive vacuolation at the disease onset. This observa-
tion, in conjunction with the absence of dilated endoplasmic
reticulum before the massive vacuolation, strongly supports the
contention that mitochondria are the source of vacuoles.
Thus, the current study suggests that mitochondrial damage is
at the center of the degeneration mechanism. Whether such
damage is caused by a direct effect of toxicity from the mutated
SOD1 or is mediated through other intermediates remains to be
determined. However, the involvement of mitochondrial degen-
eration in the early stage of the disease is consistent with a direct
effect of mutant SOD1 toxicity and perhaps is mediated by prop-
erties gained by the mutant enzyme in catalyzing redox reactions
(Beckman et al., 1993; Wiedau-Pazos et al., 1996; Yim et al.,
1996). Mitochondria are a large source of oxidative free radicals,
and the production of free radicals is directly correlated with
metabolic activity (Beal, 1996). It is possible that the high meta-
bolic activity in motor neurons, combined with the gained, toxic
oxidative properties of the mutant SOD1, causes mitochondria in
motor neurons to degenerate earlier than other neurons, trigger-
ing the onset of ALS. Consistent with this possibility are the
results of a recent report showing that mitochondria in neuro-
blastoma cells transfected with G93A mutation displayed a sig-
nificant loss of membrane potential and an increase in cytosolic
calcium concentration (Carri et al., 1997).
The assay for disease progression developed in the current
work sets the stage for further investigations of the disease
mechanism in animal models. This assay enables the study of
animals with defined disease stages, thus allowing meaningful
comparisons of pathological evolution among different SOD1
mutations. By grouping mice according to their disease stages,
inconsistencies caused by heterogeneous disease stages can be
avoided, therefore allowing a full construction of the sequence of
events (including both biochemical and morphological events)
leading to motor neuron death. The assay also provides a useful
means to evaluate the effectiveness of potential therapeutic
agents.
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